Email this article Prognostic factors in patients with hematological malignancies and concomitant chronic hepatitis C
- Authors: Nozhkin M.S.1, Lioznov D.A.1,2, Antonova T.V.1, Gorchakova O.V.1, Goldstein E.M.3, Popova M.O.1, Shneyder T.V.4
-
Affiliations:
- Pavlov First Saint Petersburg State Medical University
- Smorodintsev Research Institute of Influenza
- Harvard T.H. Chan School of Public Healt
- Leningrad Regional Clinical Hospital
- Issue: Vol 95, No 11 (2023)
- Pages: 919-923
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/231996
- DOI: https://doi.org/10.26442/00403660.2023.11.202473
- ID: 231996
Cite item
Full Text
Abstract
The study evaluated the impact of HCV infection on the prognosis in patients with hematological malignancies. A total of 96 patients with anti-HCV antibodies were enrolled, with the age of 37.8 (3.0–81.0) years old, 39.6% had non-Hodgkin’s lymphoma. Chronic hepatitis C (CHC) was diagnosed in 46.9% patients prior to malignancy development, in 38.5% patients simultaneously with malignancy, and in 14.6% patients during malignancy treatment. Clinical and biochemical signs of HCH were mild in most of the patients, minimal liver fibrosis (F0–1 by METAVIR system) was discovered in 47.3% patients, severe fibrosis or cirrhosis (F3–4) was diagnosed in 40% of participants. Only 20 (20.8%) of patients received antiviral therapy against HCV prior to enrollment. Regression analysis demonstrated that age >55 years old, late onset of antiviral therapy, and poor nutritional status were significant predictors of death from hematological malignancy. Survey conducted among physicians of hematological oncology hospitals in Saint-Petersburg revealed gaps in knowledge on presentation and risks of HCV infection, as well as on opportunities of modern antiviral therapy.
Full Text
##article.viewOnOriginalSite##About the authors
Mikhail S. Nozhkin
Pavlov First Saint Petersburg State Medical University
Email: dlioznov@yandex.ru
ORCID iD: 0000-0003-4828-6709
кандидат медицинских наук, ассистент кафедры инфекционных болезней и эпидемиологии
Russian Federation, Saint PetersburgDmitry A. Lioznov
Pavlov First Saint Petersburg State Medical University; Smorodintsev Research Institute of Influenza
Email: dlioznov@yandex.ru
ORCID iD: 0000-0003-3643-7354
доктор медицинских наук, доцент, зав. кафедры инфекционных болезней и эпидемиологии, директор ФГБУ «НИИ гриппа имени А.А. Смородинцева»
Russian Federation, Saint Petersburg; Saint PetersburgTamara V. Antonova
Pavlov First Saint Petersburg State Medical University
Email: dlioznov@yandex.ru
ORCID iD: 0000-0002-1784-6235
доктор медицинских наук, профессор, профессор кафедры инфекционных болезней и эпидемиологии
Russian Federation, Saint PetersburgOlga V. Gorchakova
Pavlov First Saint Petersburg State Medical University
Email: dlioznov@yandex.ru
ORCID iD: 0000-0001-5458-4329
кандидат медицинских наук, научный сотрудник лаб. хронических вирусных инфекций Научно-исследовательского центра
Russian Federation, Saint PetersburgEdward M. Goldstein
Harvard T.H. Chan School of Public Healt
Email: dlioznov@yandex.ru
ORCID iD: 0000-0002-6795-0559
кандидат физ.-мат. наук, старший научный сотрудник Гарвардской школы общественного здравоохранения
United States, BostonMarina O. Popova
Pavlov First Saint Petersburg State Medical University
Email: dlioznov@yandex.ru
ORCID iD: 0000-0001-8536-5495
кандидат медицинских наук, врач-гематолог отделения трансплантации костного мозга для взрослых Научно-исследовательского института детской онкологии, гематологии и трансплантологии имени Р.М. Горбачевой, доцент кафедры гематологии, трансфузиологии, трансплантологии с курсом детской онкологии факультета послевузовского образования имени профессор Б.В. Афанасьева
Russian Federation, Saint PetersburgTatyana V. Shneyder
Leningrad Regional Clinical Hospital
Author for correspondence.
Email: dlioznov@yandex.ru
врач-гематолог, зав. отделением онкогематологии, гл. внештатный гематолог Ленинградской области
Russian Federation, Saint PetersburgReferences
- ВОЗ: Глобальный доклад по гепатиту. Всемирная организация здравоохранения. 2017. Режим доступа: https://www.who.int/hepatitis/publications/global-hepatitis-report2017. Ссылка активна на 20.02.2021 [WHO: Global report on hepatitis. World Health Organization. 2017. Available at: https://www.who.int/hepatitis/publications/global-hepatitis-report2017. Accessed: 20.02.2021 (in Russian)].
- Coppola N, Alessio L, Onorato L, et al. Epidemiology and management of hepatitis C virus infections in immigrant populations. Infect Dis Poverty. 2019;8(1):17. doi: 10.1186/s40249-019-0528-6.
- Вирусные гепатиты в Российской Федерации. Аналитический обзор. 11 вып. Под ред. В.И. Покровского, А.А. Тотоляна. СПб.: ФБУН НИИЭМ им. Пастера, 2018 [Virusnyie gepatity v Rossiiskoi Federatsii. Analiticheskii obzor. 11 vyp. Pod red. VI Pokrovskogo, AA Totolana. Saitn Petersburg: FBUN NIIEM im. Pastera, 2018 (in Russian)].
- Torres HA, Pundhir P, Mallet V. Hepatitis C Virus Infection in Patients With Cancer: Impact on Clinical Trial Enrollment, Selection of Therapy, and Prognosis. Gastroenterology. Elsevier, 2019;157(4):909-16. doi: 10.1053/j.gastro.2019.01.271.
- Frigeni M, Besson C, Visco C, et al. Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Leukemia. 2020;34(5):1462-6. doi: 10.1038/s41375-019-0687-2.
- McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int. 2012;32(01):151-6. doi: 10.1111/j.1478-3231.2011.02706.x.
- Сагалова О.И., Синеглазова А.В. Осведомленность врачей-терапевтов и врачей общей практики о гепатите С. Результаты опроса. Терапевтический архив. 2020;92(11):5-12 [Sagalova OI, Sineglazova AV. Hepatitis C awareness among therapists and general practitioners. Survey results. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(11):5-12 (in Russian)].
- Pozzato G, Mazzaro C, Dal Maso L, et al. Hepatitis C virus and non-Hodgkin’s lymphomas: Meta-analysis of epidemiology data and therapy options. World J Hepatol. 2016;8(2):107-16. doi: 10.4254/wjh.v8.i2.107.
- Torres HA, Shigle TL, Hammoudi N, et al. The oncologic burden of hepatitis C virus infection: A clinical perspective. CA Cancer J Clin. 2017;67(5):411-31. doi: 10.3322/caac.21403. Epub 2017 Jul 6.
- Жданов К.В., Козлов К.В., Сукачев В.С. Гепатит С и неалкогольная жировая болезнь печени у пациентов с ВИЧ-инфекцией. ВИЧ-инфекция и иммуносупрессии. 2017;9(1):36-42 [Zhdanov KV, Kozlov KV, Sukachev VS. Hepatitis c and nonalcoholic fatty liver disease in hiv infected patients. HIV Infection and Immunosuppressive Disorders. 2017;9(1):36-42 (in Russian)].
- Mohamed AA, Hemeda AA, Aziz RK, et al. Body mass index (BMI) and alpha-fetoprotein (AFP) level correlate with the severity of HCV-induced fibrosis in a cohort of Egyptian patients with chronic HCV. Future Journal of Pharmaceutical Sciences. 2020;6(1):71.
- Chun HS, Kim BK, Park JY, et al. Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol. 2020;32(3):378-85. doi: 10.1097/MEG.0000000000001512.
- Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000;47(1):131-6. doi: 10.1136/gut.47.1.131.
- Антонова Т.В., Побегалова О.Е., Ножкин М.С., и др. Влияние вирусных инфекций на результаты трансплантации гемопоэтических стволовых клеток у онкогематологических пациентов. Журнал инфектологии. 2021;12(5):85-92 [Antonova TV, Pobegalova OE, Nozhkin MS, et al. The impact of viral infections on the results of hemopoietic stem cell transplantation in patients with hematologic malignancies. Journal Infectology. 2020;12(5):85-92 (in Russian)].
